NDA 209241 · Neurocrine
Ingrezza
Valbenazine Tosylate · Oral
NovelBreakthrough therapyPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Oct 23, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2017
Apr 11, 2017
Approved uses
3
Original approval plus efficacy supplements
Registered trials
33
9 Phase 3, 3 recruiting
FAERS reports
25,388
6,141 serious, 1,314 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: DEPRESSION AND SUICIDAL IDEATION AND BEHAVIOR IN PATIENTS WITH HUNTINGTON’S DISEASE VMAT2 inhibitors, including INGREZZA and INGREZZA SPRINKLE, can increase the risk of depression and suicidal thoughts and behavior in patients with Huntington’s disease. Anyone considering the use of INGREZZA or INGREZZA SPRINKLE must balance the risks of depression and suicidal ideation and behavior with the clinical need for treatment of chorea. Closely monitor patients for the emergence or worsening of depression, suicidal ideation, or unusual changes in behavior. Inform patients, their caregivers, and families of the risk of depression and suicidal ideation and behavior and instruct them to report behaviors of concern promptly to the treating physician. Particular caution should be exercised in treating patients with a history of depression or prior suicide attempts or ideation, which are...
What it is approved for
From the label in effect Apr 17, 2026.
INGREZZA and INGREZZA SPRINKLE are indicated for the treatment of adults with: - tardive dyskinesia [see Clinical Studies ( 14.1 )] . - chorea associated with Huntington’s disease [see Clinical Studies ( 14.2 )] . INGREZZA and INGREZZA SPRINKLE are vesicular monoamine transporter 2 (VMAT2) inhibitors indicated for the treatment of adults with: - tardive dyskinesia. ( 1 ) - chorea associated with Huntington’s disease. ( 1 )
Mechanism: The mechanism of action of valbenazine for the treatment of tardive dyskinesia and chorea in patients with Huntington’s disease is unclear, but is thought to be mediated through the reversible inhibition of vesicular monoamine transporter 2 (VMAT2), a transporter that regulates monoamine uptake from the cytoplasm to the synaptic vesicle for storage and release.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 18, 2023 Supplement 26 · Efficacy OrphanLabelLetter
- Apr 23, 2021 Supplement 20 · Efficacy LetterLabel
- Apr 11, 2017 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyOrphanLetterLabelReview
3 products under this application
- INGREZZA · VALBENAZINE TOSYLATE EQ 80MG BASE · CAPSULE, ORAL · Prescription · TE AB
- INGREZZA · VALBENAZINE TOSYLATE EQ 60MG BASE · CAPSULE, ORAL · Prescription · TE AB
- INGREZZA · VALBENAZINE TOSYLATE EQ 40MG BASE · CAPSULE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Valbenazine" as an intervention, any sponsor and status, largest first.
- Journey Study: Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment for SchizophreniaPivotal-lookingCompleted
Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
NCT05110157 · 442 participants · Start Nov 29, 2021 · Primary completion Feb 4, 2025
Drug: Placebo; Valbenazine · For: Schizophrenia
Sites: Phoenix, Arizona; Rogers, Arkansas; Anaheim, California · 87 sites in all
- A Phase 3 Study of NBI-98854 for the Treatment of Tardive DyskinesiaPivotal-lookingCompleted
Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
NCT02274558 · 234 participants · Start Oct 2014 · Primary completion Sep 2015
Drug: NBI-98854; Placebo · For: Tardive Dyskinesia
Sites: Little Rock, Arkansas; Anaheim, California; Glendale, California · 54 sites in all
- Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive DyskinesiaPivotal-lookingCompleted
Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
NCT02405091 · 167 participants · Start Mar 2015 · Primary completion Mar 2017
Drug: NBI-98854 · For: Tardive Dyskinesia
Sites: Anaheim, California; Glendale, California; Irvine, California · 48 sites in all
- Rollover Study for Continuing Valbenazine (NBI-98854) Administration for the Treatment of Tardive DyskinesiaPivotal-lookingCompleted
Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
NCT02736955 · 161 participants · Start Jun 13, 2016 · Primary completion Jun 30, 2017
Drug: Valbenazine · For: Tardive Dyskinesia
Sites: Anaheim, California; National City, California; Norwalk, California · 27 sites in all
- Safety and Tolerability Study of NBI-98854 for the Treatment of Subjects With Tourette SyndromeCompleted
Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
NCT02879578 · 155 participants · Start Jul 25, 2016 · Primary completion Nov 1, 2017
Drug: Valbenazine · For: Tourette Syndrome
Sites: Sun City, Arizona; San Diego, California; Loxahatchee Groves, Florida · 13 sites in all
- Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington DiseasePivotal-lookingTerminated
Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
NCT04400331 · 154 participants · Start Sep 18, 2020 · Primary completion Nov 5, 2025
Drug: Valbenazine · For: Chorea, Huntington
Sites: Birmingham, Alabama; Little Rock, Arkansas; La Jolla, California · 34 sites in all
- Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive DyskinesiaPivotal-lookingCompleted
Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
NCT03891862 · 135 participants · Start Mar 18, 2019 · Primary completion Dec 23, 2019
Drug: Valbenazine; Placebo oral capsule · For: Tardive Dyskinesia (TD)
Sites: Little Rock, Arkansas; Anaheim, California; Costa Mesa, California · 43 sites in all
- Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated With Huntington DiseasePivotal-lookingCompleted
Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
NCT04102579 · 128 participants · Start Nov 13, 2019 · Primary completion Oct 15, 2021
Drug: Valbenazine; Placebo · For: Chorea, Huntington
Sites: Birmingham, Alabama; Little Rock, Arkansas; La Jolla, California · 46 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective2,780
- somnolence2,504
- fatigue1,699
- tremor1,611
- tardive dyskinesia1,537
- fall1,149
- dizziness968
- death946
- drooling926
- dyskinesia904
- therapeutic product effect decreased893
- off label use697
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2017 | 1,145 |
| 2018 | 3,935 |
| 2019 | 3,742 |
| 2020 | 4,036 |
| 2021 | 6,279 |
| 2022 | 1,723 |
| 2023 | 1,170 |
| 2024 | 1,124 |
| 2025 | 1,187 |
| 2026 | 1,047 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Ingrezza (Valbenazine Tosylate)
2024 spending
$1.96B
Beneficiaries
32,171
254,899 claims
Per beneficiary
$60,819
$272.77 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $788,822,963 |
| 2021 | $918,612,514 |
| 2022 | $1,266,279,975 |
| 2023 | $1,705,132,723 |
| 2024 | $1,956,616,319 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Treatment Recommendations for Tardive Dyskinesia.
Ricciardi L, Pringsheim T, Barnes TRE, et al. · Can J Psychiatry 2019 · Systematic Review
- KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia.
Hauser RA, Factor SA, Marder SR, et al. · Am J Psychiatry 2017 · Clinical Trial, Phase III, Comparative Study
- Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington's disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial.
Furr Stimming E, Claassen DO, Kayson E, et al. · Lancet Neurol 2023 · Randomized Controlled Trial, Clinical Trial, Phase III
- Updating the recommendations for treatment of tardive syndromes: A systematic review of new evidence and practical treatment algorithm.
Bhidayasiri R, Jitkritsadakul O, Friedman JH, et al. · J Neurol Sci 2018 · Research Support, Non-U.S. Gov't, Systematic Review
- Efficacy and acceptability of pharmacological interventions for tardive dyskinesia in people with schizophrenia or mood disorders: a systematic review and network meta-analysis.
Solmi M, Fornaro M, Caiolo S, et al. · Mol Psychiatry 2025 · Systematic Review, Network Meta-Analysis
- Real-World Experience With VMAT2 Inhibitors.
Niemann N, Jankovic J · Clin Neuropharmacol 2019 · Pragmatic Clinical Trial
Sponsor: Neurocrine Biosciences
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.